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Abstract 
Phospholipids and their derivatives represent a broad range of multifunctional substances used as excipi-
ents or active ingredients by different industries due to their natural origin and unique properties. A fast 
and reliable quantification as well as comprehensive stability evaluation are of major importance in the 
process of development and quality control of lipid-based systems. Therefore, the present study is fo-
cused on the development and validation of a rapid ultra-high performance liquid chromatography – 
charged aerosol detector based (UHPLC-CAD) method for simultaneous detection of a multitude of natu-
ral and synthetic lipids, (charged) phospholipids, lipophilic fluorescent markers and their possible degra-
dation products. Twenty-two compounds were characterized by a strong linear response of the detector 
(R² > 0.97). Moreover, remarkable limits of detection (≤ 10 µg/mL) and limits of quantification 
(≤ 25 µg/mL) associated with a consistent reproducibility were achieved for all tested molecules. The 
performance of the analytical method was demonstrated by analyzing the lipid composition (after differ-
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ent production stages and photodegradation) of both bupivacaine loaded liposomes and a Doxil®-like 
formulation. The newly developed method combines a rapid, comprehensive, and efficient quantification 
with minimal economic effort and ecologic consequences, meeting the requirements of modern analyti-
cal processes and offering a broad range of possible applications in various industrial sectors and scien-
tific laboratories. 
 
Keywords: UHPLC-CAD method, phospholipid detection, phospholipid quantification, liposomes, charged 
aerosol detector 
 
1. Introduction  
Phospholipids and their derivatives represent a broad range of multifunctional substances used as excip-
ients or active ingredients by different manufacturing branches due to their unique properties and their 
natural origin. They are characterized by a hydrophilic headgroup composed of a phosphate-coupled 
choline, serine, glycerol or ethanolamine linked to a glycerol backbone esterified with up to two hydro-
phobic fatty acid chains leading to the molecules amphiphilic characteristics [1,2]. Phospholipids are 
described as main component of cellular membranes and are therefore characterized by a practically 
nonexistent toxicity making them ideal components for food and cosmetic industry [3,4]. Indeed, phos-
pholipids find their technological application as emulsifiers, antioxidants, surface-active compounds, 
wetting agents or skin penetration enhancer [5,6]. Furthermore, following their pivotal physiological 
function, phospholipids are used to produce complex colloidal systems like liposomes, solid lipid nano-
particles and artificial cell-like vesicles to generate versatile biomaterials and smart therapeutics for con-
trolled drug delivery [4,7,8]. Being the first nano-sized drug carrier approved in 1995 by the Food and 
Drug Administration (FDA), liposomes underwent a great development as drug delivery system and con-
tinuous efforts have been made to build on their clinical success. Nowadays, a vast indication range is 
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covered by liposomal formulations, such as management of cancer, pain therapy, vaccination and treat-
ment of severe fungal infections [9]. In the last decades, the major focus in liposome technology shifted 
from a plain quest for improved bioavailability of poorly water-soluble drugs to a multifaceted approach 
aimed either at enhancing the therapeutic efficacy by a specific targeting or by a controlled and pro-
longed drug release. To meet this goal a large variety of (semi-)synthetic components such as charged 
phospholipids, polyethylenglycol (PEG-) derivates, surfactants and other specific long-chained lipids like 
non-exchangeable membrane staining indocarbocyanine dyes (DiO, DiD; vide infra) could be introduced 
in the formulation, resulting in very complex compositions [10,11]. In all the above-mentioned areas, 
qualitative and quantitative analysis of the used phospholipids is of paramount interest for the develop-
ment of new products, during the continuous monitoring of the production process or in final quality 
controls. The oldest methodology to quantify (phospho)lipids in liposomal formulations is based on the 
use of color reagents able to form complexes, then analyzed spectrophotometrically. The most estab-
lished colorimetric methods for phospholipid analysis are the Bartlett assay and Stewart assay [12,13]. 
While the Bartlett assay is based on the analysis of inorganic phosphate occurring after the oxidation of 
phospholipids with perchloric acid and the subsequent reaction with ammonium molybdate, the Stewart 
assay enables to detect only organic phosphate after complexing phospholipids with ammonium fer-
rothiocyanate in chloroform. Both methods require different preparation steps and are therefore prone 
to an inter-user variability and a high error rate. Furthermore, only the total phospholipid concentration 
could be determined; molar ratios of multicomponent mixtures and their specific degradation products 
as well as other lipids than phospholipids cannot be analyzed with these methods making them ineffec-
tual for routine quality control [14,15]. An instrumental approach able to evaluate a majority of the 
above-mentioned parameters is the analysis via gas chromatography (GC). This technique has the ad-
vantage of providing information about the exact fatty acid composition of single substances. However, a 
GC-based assay requires the derivatization of phospholipids to vaporable substances via acid-catalyzed 
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methanolysis to form fatty acid methyl esters (FAMEs) representing a critical, error-prone step [16,17]. 
Furthermore, being a definite differentiation of the individual element of a multicomponent liposomal 
formulation by means of GC not achievable, this technique results unsuitable for quality control and pro-
cess monitoring. 
A possible method for an efficient quantification of different components, impurities and degradation 
products is a gradient-based high-performance liquid chromatography (HPLC) or ultra-high-performance 
liquid chromatography (UHPLC) [18]. Regrettably, the absence of chromophores in lipids encumbers the 
analysis of all components with commonly available UV-diode array detectors (UV-DAD) and fluorescence 
detectors [19]. The most sophisticated method to identify different headgroups and acyl chains, and the 
resulting differences in polarity and charge, is detecting phospholipids by means of a mass spectrometer 
(MS) coupled to an UHPLC. This method also offers the opportunity of analyzing different substances 
eluting with the same retention time [20]. However, the costs of an MS detector compared to conven-
tional ones, the need for experienced users, and the specific maintenance required disqualifies this tech-
nology from becoming the ideal routine (phospho)lipid analytics in conventional quality control [20]. In 
the event substances lack a chromophore general-purpose detectors such as refractive index detectors 
(RID), evaporative light scattering detectors (ELSD), condensation nucleation light scattering detectors 
(CNLSD) or charged aerosol detectors (CAD) could be employed [21–23]. Despite its attractively low costs 
and uncomplicated mode of operation, a gradient-based separation induces a permanent change in the 
refractive index making the detection with RID impossible [24]. In contrast to the RID, CAD, CNLSD and 
ELSD enable the detection even upon gradient-based separation. All three detectors can identify non-
volatile substances relative to their volatile mobile phase [25,26]. Among them, the CAD offers the ability 
to detect semi-volatile substances like short-chained lipid components [15,27].  
In a typical CAD setup, schematically shown in Figure 1, the mobile phase containing the separated ana-
lytes is nebulized by means of nitrogen to form small aerosol droplets in the CAD after passing the DAD. 
 
 
5 
After removing aerosol droplets too large for evaporation, the eluent and all volatile substances are 
evaporated in a tempered nebulizing chamber to form dried particles of the analyte. These particles are 
then combined with charged nitrogen generated by means of a corona discharge needle in the ionizer. 
After passing an ion trap that removes excess ions and high mobility particles, the aggregate charge of 
the remaining aerosol particles is measured by an electrometer which generates the signal [27]. 
The aim of the present study is the development and validation of a rapid UHPLC-DAD-CAD-based meth-
od for simultaneous detection of a wide range of natural and synthetic lipids, phospholipids, their degra-
dation products and non-exchangeable fluorescent lipid markers used in the development and prepara-
tion of liposomal formulations. Furthermore, a liposomal bupivacaine formulation (BUP-liposomes) was 
then used to demonstrate the analytical method either for quality control or for the quantification of 
degradation. These BUP-liposomes represent a novel strategy for the development of drug delivery sys-
tems for sustained drug release and are based on negatively charged phospholipids (NCP) in the liposo-
mal membrane using an in situ depot formation by controlled aggregation with divalent cations [28]. The 
encapsulation of a local anesthetic like bupivacaine could trigger a long-lasting pain reduction. Addition-
ally, a liposomal formulation mirroring the market product Doxil was analyzed with the developed meth-
od as proof-of-principle for commercial liposome compositions. Although the applicability of the new 
UHPLC-CAD method is demonstrated for liposomal formulations only, the method is universal and could 
be applied in any possible field of interest working with phospholipids. 
 
 
2. Materials and Methods 
2.1 Material. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-2-oleoyl-glycero-
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3-phosphocholine (POPC), 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) 
(DOPG), 1,2-dipalmitoyl-sn-glycero-3-phosphate sodium salt (DPPA), 1,2-distearoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) sodium salt (DSPG), 1,2-dioleoyl-sn-glycero-3-phosphate sodium salt (DOPA), N-
(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (sodium 
salt) (DSPE-mPEG-2000), hydrogenated L-α-phosphatidylcholine from soy (HSPC), L-α-
phosphatidylcholine from soy (SPC), L-α-phosphatidylcholine from egg (EPC) and sphingomyelin from egg 
(ESM) were kindly gifted by Lipoid (Ludwigshafen, Germany). 1,2-dipalmitoyl-sn-glycero-3-
phospho((ethyl-1',2',3'-triazole)triethyleneglycolmannose) (ammonium salt) (DPPA-PEG2-Mannose), 1,2-
dioctadecanoyl-sn-glycero-3-phosphate (sodium salt) (1,2-dioctadecanoyl-sn-glycero-3-phosphate (sodi-
um salt) (DSPA), 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine (sodium salt) (DPPS), 1-hexadecanoyl-2-
(9Z-octadecenoyl)-sn-glycero-3-phospho-L-serine (sodium salt) (POPS),  L-alpha-phosphatidylserine 
(brain, porcine) (sodium salt) (BrainPS)  and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt) 
(DOPS) were purchased from Avanti Polar Lipids (Alabaster, USA). 3,3'-dioctadecyloxacarbocyanine per-
chlorate (DiO) and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate 
Salt (DiD) were bought from Thermo Fisher Scientific (Waltham, MA, USA). Cholesterol (CHOL), palmitic 
acid, oleic acid, stearic acid and lidocaine hydrochloride were obtained from Merck (Darmstadt, Germa-
ny), trifluoracetic acid (TFA) and sodium chloride (NaCl) were obtained from Carl Roth (Karlsruhe, Germa-
ny). Bupivacaine (BUP) hydrochloride was obtained from Fagron (Glinde, Germany). All solvents used for 
the mobile phase were obtained by Fisher Scientific (Schwerte, Germany).  
2.2 UHPLC-DAD-CAD assay. The quantification of all samples was performed by means of an Ultimate 
3000 HPLC system (Thermo Fisher Scientific, Basel, Switzerland). The instrument was equipped with a 
quaternary pump (LPG-3400SD), an autosampler (WPS-3000), a thermostatted column compartment 
(TCC-3000), a DAD (DAD-3000) and a CAD (Corona Veo RS). Chromeleon 7.2 software was used for data 
evaluation and instrument control. A Hypersil Gold™ column (C18, 150 x 2.1 mm) with a particle size of 
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1.9 µm and a pore size of 175 Å (Thermo Fisher Scientific, Basel, Switzerland) was used at a temperature 
of 50 °C as stationary phase. During the time of analysis, samples were kept refrigerated at 6 °C in the 
autosampler. The injection volume was 5 μL and the flow rate was set at 0.7 mL min-1. Three different 
eluents, eluent A: acetonitrile +0.2% v/v trifluoracetic acid (TFA), eluent B: methanol (MeOH) +0.2% v/v 
TFA and eluent C: ultrapure water +0.2% v/v TFA were used to create a linear gradient in the mobile 
phase. The analysis started with 35% eluent A, 50% eluent B and 15% eluent C at time point 0 min. After 
20 min, the mobile phase was composed of 5% eluent A and 95% eluent B and kept constant for 1.5 min. 
At 23 min, the composition of eluents was brought back to the initial state and the column was equili-
brated for additional 3 min. For the Corona Veo RS, the gas evaporation temperature was adjusted to 
45 °C and the response rate was set to 100 pA. 
2.3 Quantification of phospholipids. Prior to injection, lipid stock solutions used for the calibration were 
prepared in MeOH. After diluting the stock solutions to appropriate concentrations, samples were then 
additionally diluted with the internal standard (IS, palmitic acid in MeOH 200 µg mL-1) in a ratio of 1:2 to 
achieve a concentration of 100 µg mL-1 of IS in the sample. If not stated otherwise, the calibration for 
synthetic (phospho)lipids was performed at concentrations between 0.1 and 100 µg mL-1, while the range 
for natural phospholipids was 0.1 - 1000 µg mL-1.  
2.4 Method validation. The validation of this HPLC method was done in accordance to ICH-Q2A and Q2B 
guidelines [29,30]. Linearity was assessed with a regression line by the method of least squares 
(GraphPad Prism 8.0). The limit of detection (LOD) and the limit of quantification (LOQ) were determined 
using the signal-to-noise ratio (S/N ratio) calculated by the Chromeleon software. The LOD was set to a 
S/N ratio larger than 2 and the LOQ to a S/N ratio larger than 10. The reproducibility of the calibration 
method was done by an intra-laboratory repetition of the calibration of DPPC, DOPC and POPC. The accu-
racy of the method was checked by measuring solutions of known concentrations (100, 50 and 25 µg mL-
1) of DPPC, DOPC and POPC and expressing the deviation in percentage from the anticipated concentra-
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tion. The robustness of the method was assessed by implementing minor alterations in column oven 
temperature (T = ±2 K), variations in the flow rate (Vf = 0.675 mL min-1 and Vf = 0.65 mL min-1 instead of 
Vf = 0.70 mL min-1) and CAD gas evaporation temperature (T = ±5 K) of the analytical method. 
2.5 Production of liposomes and encapsulation of bupivacaine. Two different formulations of liposomes 
were produced: (i) liposomes containing DSPG, CHOL and DPPC (25:30:45 mol%) with a total lipid con-
centration of 50 mM and (ii) liposomes containing HSPC, CHOL and DSPE-PEG-2000 (56.5:38.2:5.3 mol%) 
with a total lipid concentration of 21.6 mM according to the composition of Doxil using film hydration 
method [31–33]. Briefly, after the preparation of stock solutions with appropriate organic solvents, lipids 
were mixed and the lipid film was produced by nitrogen stream and subsequent vacuum overnight. Large 
unilamellar vesicles were formed by hydrating the lipid film with an appropriate buffer. After undergoing 
six freeze-thaw-cycles, liposomes were extruded through a 200 nm- (formulation i) or a 100 nm-pore size 
(formulation ii) polycarbonate membrane (Whatman, GE Healthcare, Illinois, USA) by means of a Lipex 
Extruder (Evonik Industries AG, Essen, Germany). The drug BUP, a weak base with a reported pKa of 8.1, 
was then remotely loaded into liposome formulation (i) using an active encapsulation method based on a 
transmembrane ammonium gradient [34,35]. The transmembrane ammonium gradient was created by 
size exclusion chromatography (SEC) with Sephadex G50 (GE Healthcare, Illinois, USA) equilibrated with 
150 mM NaCl solution in ultrapure water using a centrifuged-based spin protocol (3 min at 1000 g) to 
avoid further dilution of the sample. Subsequently, liposomes were incubated with BUP at an initial mo-
lar drug-to-lipid ratio (D/L) of 5 for 30 min at 70 °C. The non-encapsulated BUP was removed by an addi-
tional SEC step. The phospholipid amount at different stages of the production process was quantified by 
HPLC as well as the initial and final BUP concentration. Afterwards, the encapsulated BUP and the final 
D/L ratio could be calculated. 
2.6 Quantification of bupivacaine by HPLC. For the quantification of BUP the above-mentioned HPLC 
system was used. The stationary phase, a Nucleosil C18 EC (250 mm x 4 mm) with a particle size of 5 µm 
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(Macherey-Nagel, Düren, Germany), was kept at 50 °C. A linear gradient method with a flow rate of 1 mL 
min-1 with eluent A: ACN with 0.1% v/v TFA and eluent B: ultrapure water with 0.1% v/v TFA was used. 
The method started with 25% of eluent A changing to an equal mixture after 15 min. Afterwards, the 
composition was changed to 99% eluent A. After reaching the initial composition of the mobile phase 
after 20 min, the column was equilibrated for further 5 min. The injection volume was 5 µL. Lidocaine 
hydrochloride (200 µg mL-1) was used as internal standard (IS) and mixed with the samples in a ratio of 
1:2 to achieve a final concentration of 100 µg mL-1 of IS. Both drugs were detected with a DAD at λ = 220 
nm. 
2.7 Size distribution and zeta potential measurements. The size distribution of the liposomes was de-
termined by dynamic light scattering. Samples diluted to a concentration of 0.75 mM in ultrapure water 
were measured at 25 °C using a Litesizer 500 (Anton Paar, Graz, Austria) with a λ = 658 nm laser and 175° 
backscatter angle in a disposable cuvette (Sarstedt, Nümbrecht, Germany). The zeta potential was de-
termined by means of continuously-monitored phase-analysis light scattering (cmPALS) in an Omega cu-
vette (Anton Paar, Graz, Austria). The intensity size distribution of the liposomes was typically unimodal; 
therefore, the autocorrelation function was analyzed according to the cumulant method. 
2.8 Photodegradation. Degradation of BUP-loaded liposomes was induced by strong UV radiation expo-
sure and high temperature in a UVA Cube 100 (Dr. Hönle AG, München, Germany) equipped with an iron-
radiator and quartz-filter. Samples were exposed to UV radiation (100 W) up to 36 h. After given time 
points, stability data (lipid and BUP content, hydrodynamic diameter, PDI and zeta potential) were ana-
lyzed. 
2.9 Statistical evaluation. All measurements were carried out in triplicate and the values are represented 
as mean ± standard. For results based on calculations with experimental triplicates, the propagated un-
certainty of error is displayed. 
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3. Results and Discussion 
3.1 Quantification of phospholipids – Method development and validation. An immediate and reliable 
quantification, as well as comprehensive stability evaluation for quality control, are of paramount im-
portance in every manufacturing process. With the aim of obtaining an efficient, not MS-coupled profil-
ing strategy for a multitude of phospholipids-based products, we developed a HPLC-DAD-CAD method 
that would enable a remarkably rapid and simultaneous detection of routine components of (phos-
pho)lipid mixtures and of liposomal components. Differently from other reported methods [36–40], low 
LODs and LOQs could be obtained injecting very small sample volumes (5 µL). Figure 2 shows overlaid 
chromatograms of different groups of (phospho)lipids and other liposome-related substances. For a bet-
ter overview they are separated by headgroup or origin: synthetic phosphatidylcholines (Figure 2a), natu-
ral phosphatidyl choline blends SPC and EPC (Figure 2b), sphingomyelin and hydrogenated SPC (Fig-
ure 2c), negatively charged phospholipids with phosphatic acid headgroup (Figure 2d), negatively charged 
phospholipids with phosphatidylglycerol headgroup (Figure 2e), negatively charged phospholipids with 
phosphatidylserine headgroup (Figure 2f), fatty acids (Figure 2g) and lipophilic fluorescent tracers detect-
ed with the DAD (Figure 2h). It can be clearly appreciated that the method enables not only to separate 
different classes of (phospho)lipids, but also (phospho)lipids differing slightly in their lipid chains (e.g. 
DPPC, POPC and DOPC (Figure 2a)). A possible mixture of different (phospho)lipids used in the develop-
ment of drug delivery systems are shown in Figure S1 proving the sensitivity of the method and the broad 
application possibilities.  
Beside the broad area of application, analytical factors like linearity, reproducibility, robustness and accu-
racy described by the International Conference of Harmonization (ICH) guidelines Q2 (R1) need to be 
fulfilled. For the evaluation of linearity, three independent stock solutions of each lipid were prepared in 
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chloroform. For the natural phospholipids and multicomponent mixtures (EPC, SPC, HSPC, ESM,), concen-
tration ranges from 1 mg mL-1 (500 µg mL-1 for BrainPS) to 1 µg mL-1 were used. The stock solutions for 
(synthetic) pure substances (CHOL, DPPC, DOPC, POPC, DSPC, DPPA, DSPA, DOPA DSPG, DOPG, DPPS, 
DOPS, POPS, DSPE-mPEG-2000, DPPA-PEG3-mannose) were prepared in a range of 100 µg mL-1 (50 µg 
mL-1 for DSPE-mPEG-2000) to 0.5 µg mL-1. The linearity of the lipid-based fluorescent dyes DiO and DiD 
was assessed between 25 and 0.5 µM representing a commonly used concentration range in liposomal 
formulations. After analysis, the area under the curve (AUC) of the peak for single components (main 
peak for multicomponent substances) were analyzed and divided through the AUC of the IS. The given 
ratio ± standard deviation was plotted against the concentration of the solution. Although CAD detectors 
are known for their non-linear behavior [41], all the various analysed components show a strong linearity 
in the chosen formulation-based concentration range given in Table 1. Every obtained linear regression is 
characterized by a coefficient of determination of R2 ≥ 0.97 and a low signal intensity based standard 
error of regression of Sy.x ≤ 1.3 for all tested components indicating a strong correlation between the 
AUC and the initial concentration and fulfilling the criterion of linearity. 
The analytical sensitivity of the method was assessed by means of LOD and LOQ as described in the 
Methods. For the determination of the LOD/LOQ of the natural phospholipids represented by several 
peaks, the calculations are based on the main peak (peak with highest AUC). Results shown in Table 1 
indicate a sufficient LOD and LOQ for all analytes. Using an UHPLC-coupled CAD detector, much lower 
LOD and LOQ could be achieved in comparison to an HPLC-coupled ELSD detector [42,43]. Compared to 
other UHPLC methods using the CAD detector, our LOD and LOQ values are in the same range or below 
[43–46]. 
The reproducibility of the method was tested by repetition of the calibration curves of DPPC, DOPC and 
POPC. The results of the respective two calibration curves are shown in Figure S2. All analyzed probes 
show an excellent correlation and reproducibility.  
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For the evaluation of accuracy, five independent solutions of three different components (DPPC, DOPC 
and POPC) with known concentrations were prepared. After the analysis, the concentration of phospho-
lipid was determined and the percentage deviation from the nominal concentration based on the calibra-
tion curves was calculated (Table S1). Although there is a trend of increasing deviations by decreasing 
concentrations of the sample, all samples showed a deviation from the nominal concentration of less 
than 5% which fulfills the criterion of accuracy. 
Modern UHPLC systems constantly monitor all parameters (flow rate, gradient composition, column oven 
temperature, lamp house temperature of the DAD, gas pressure, ion trap voltage of the CAD, etc.) im-
portant for the evaluation of the exactness of the method. As requested by the ICH-Q2A and Q2B guide-
lines, a robustness test should demonstrate that minor changes of method parameters (flow rate/ col-
umn oven temperature/ CAD gas evaporation temperature) or malfunction of intrasystem control mech-
anisms only minimally affect the precision of the analysis and a method transfer to other machines from 
other suppliers could be possible without mayor disadvantages following specific transfer protocols [47]. 
Thanks to modern UHPLC-systems, serious alterations in the underlying conditions lead to an automated 
shut down of the analysis (in our analytical system, any changes of flow rate or changes in column oven/ 
CAD gas evaporation temperature of > 0.5 °C). Nevertheless, a physical mixture of three components 
(DPPC, DOPC, POPC) showing minor distinctions in the retention time were analyzed using altered meth-
od parameters to fulfill ICH-Q2A and Q2B guideline's requirements. Changing the temperature results in 
minor positive (48 °C, +3.41%) and negative (52 °C, -2.66%) variations in the retention time of the eluted 
samples. No considerable alteration of the AUC could be observed for both parameters, temperature and 
flow rate (Table S2). Changes in the flow are responsible for expected alterations in retention time slightly 
increasing with a decreased flow rate. Changes in CAD gas evaporation temperature only had a negligible 
effect on both flow rate (< 0.3%) and AUC (< 0.6%, Table S2). All components in each sample could be 
separated and no overlay of the different peaks occurred (Error! Reference source not found.3). Thus, 
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the outcome of the test indicates a strong robustness of the method within the given borders and offers 
the opportunity for simple method transfer.  
3.2 Applicability for quality control of liposomal formulations. The applicability of the UHPLC method 
for phospholipid quantification was tested with two different formulations, one negatively charged for-
mulation currently used in research for the development of a novel depot drug delivery systems and a 
second formulation representing the commercially available product Doxil [28,31]. Liposomes were pro-
duced by film hydration method (vide supra). Briefly, the formed vesicles were subjected to six freeze-
thaw cycles and subsequently extruded to achieve a homogenous size distribution. The first formulation, 
liposomes consisting of DSPG, CHOL and DPPC (25:30:45 mol%), was used for the active encapsulation of 
BUP. As expected, the formulation resulted homogenously dispersed, with a measured hydrodynamic 
diameter of 172.8 ± 0.8 nm and a polydispersity index (PDI) of 0.08 ± 0.02. The lipid content was analyzed 
after every production step. During the preparation and extrusion of the liposomes, no degradations 
could be observed (Figure 3). The extrusion of the liposomes led to a loss of approximately 7% in the 
total lipid concentration without inducing changes in relative lipid molar ratios. After liposome formation, 
BUP was loaded remotely using a transmembrane ammonium gradient formed by means of a buffer-
equilibrated SEC column, adapted from previous protocols [34,35]. Afterwards, the unencapsulated BUP 
was removed by eluting the BUP-containing liposomes through a second SEC column. The sequential SEC 
elutions induced a slight variation in the final total lipid concentration of the samples of approximately 
10%, nevertheless without altering the relative composition of the final formulation. The measured 
amount of encapsulated BUP was 8.2 ± 0.6 mg mL-1 with a final drug to lipid ratio (D/L ratio) of 
0.97 ± 0.09. 
The Doxil-like vesicles, formulated with HSPC, CHOL and DSPE-mPEG-2000, had a size of 131.9 ± 1.6 nm 
with a PDI of 0.07 ± 0.02. All the different components could be resolved simultaneously with the de-
scribed HPLC method as shown in Figure 4Error! Reference source not found.a. Furthermore, the quanti-
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fication showed that minor loss of lipids (1%) occurred during the preparation and extrusion of the lipo-
somes and the Doxil-like formulation was identical to the theoretical composition of the market product 
demonstrating the methods suitability for being used in regular quality control (Figure 4b).  
3.3 Photodegradation. Previously produced BUP-liposomes were subjected to a stress test to simulate 
light-induced degradation, possibly responsible of liposome instability during long term storage. After 
18 h in the UV chamber, only a moderate degradation of DSPG and DPPC could be detected. However, 
the CHOL content showed a major decrease from 8.43 ± 0.52 mM to 1.97 ± 2.15 mM (Figure 5) without 
remarkably changes in the size or zeta potential of the liposomes, only the PDI increased slightly (Figure 
S4a and b). The BUP amount remained stable at 97.5 ± 4.9%. After 36 h, no CHOL could be detected any 
longer, while 65% of DSPG and 49% of DPPC were degraded; the BUP amount was reduced to 
79.8 ± 4.2%. Based on DLS data, an unequivocal instability was induced (Figure S4a). Contrary to our as-
sumption, no free fatty acids (PA or SA) or other detectable degradation products could be analyzed after 
the photodegradation. This might origin from the unnaturally strong energy input of the UV-chamber and 
a complete degradation/oxidation of the phospholipids towards monomolecular products without the 
intermediate step of hydrolyzation [48]. The decrease of zeta potential of around 10 mV indicates the 
formation of negatively charged degradation products (Figure S4b). 
 
4. Conclusion 
The described CAD-based UHPLC method offers the opportunity of analyzing simultaneously the com-
position and stability of differently charged phospholipids, lipids, and active pharmaceutical ingredi-
ents used in commercially available formulations and in research. We could demonstrate that all the 
requirements given by the ICH-Q2A and Q2B guidelines are fulfilled. The method shows a strong linear-
ity for a broad multitude of chemically different analytes used in liposomal formulations. Furthermore, 
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a sufficient LOD/LOQ associated with an ideal reproducibility was achieved for all probes. Finally, our 
approach combines a comprehensive and efficient quantification with minimal economic and ecologic 
impact. The herein proposed method meets the requirements of modern analytical laboratories, offer-
ing a broad range of possible applications in either quality control or process observation in various 
industrial sectors and scientific laboratories. 
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Figures 
Figure 1. Schematic overview of a typical CAD setup. 
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Figure 2. HPLC chromatograms of different phospholipids, (a) synthetic, amphiphilic phospholipids with phosphati-
dylcholine headgroup, CHOL and DSPE-PEG, (b) natural, amphiphilic phospholipids EPC and SPC, (c) ESM and hydro-
genated SPC (HSPC), (d) negatively charged phospholipids with phosphatic acid headgroup, (e) negatively charged 
phospholipids with phosphatidyl glycerol headgroup, (f) negatively charged phospholipids with phosphatidylserine 
headgroup, (g) fatty acids and (h) the lipophilic fluorescent tracers DiO and DiD detected with the DAD. 
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Figure 3. Composition of liposome formulations containing 25 mol% DSPG, 30 mol% CHOL and 45 mol% DPPC dur-
ing the preparation and the encapsulation of BUP with a final D/L ratio of 0.97 ± 0.09. 
 
 
Figure 4. (a) Chromatogram of Doxil-like liposomes containing HSPC, CHOL and DSPE-mPEG-2000. (b) Theoretical 
content (molar ratio) of Doxil and composition of Doxil-like liposomes before and after extrusion. 
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Figure 5. Photodegradation of BUP liposomes. Molar concentrations of DSPG, CHOL and DPPC before and after 18 h 
and 36 h exposure time. 
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Table 1. Analyzed phospholipids with their respective retention time, the linearity range, coefficient of determina-
tion (R2), standard error of regression (Sy.x) and limit of detection (LOD) and limit of quantification (LOQ). For mix-
tures of natural phospholipids, the retention time of the main peak and the corresponding LOD and LOQ are dis-
played. 
Phospholipid Detection 
Retention 
time 
[min] 
Linearity range 
[µg mL-1] R2 Sy.x 
LOD 
[µg mL-1] 
LOQ 
[µg mL-1] 
min max 
DPPC CAD 12.21 0.5 100 0.9919 0.1441 1.0 5.0 
DSPC CAD 15.73 0.5 100 0.9906 0.1615 0.5 2.5 
DOPC CAD 12.85 0.5 100 0.9826 0.2050 0.5 2.5 
POPC CAD 12.52 0.5 100 0.9947 0.1042 0.1 2.5 
EPC CAD 12.51 1.0 1000 0.9731 0.7236 1.0 10 
SPC CAD 9.69 5.0 1000 0.9844 0.5525 10 25 
HSPC CAD 15.70 5.0 1000 0.9829 1.2910 2.5 25 
DPPA CAD 13.18 2.5 100 0.9855 0.2334 1.0 2.5 
DPPA-PEG3-mannose CAD 11.49 2.5 100 0.9989 0.0446 2.5 10 
DSPA CAD 16.78 2.5 100 0.9889 0.1810 5.0 25 
DOPA CAD 13.74 2.5 100 0.9747 0.2255 1.0 25 
DSPG CAD 16.06 0.5 100 0.9843 0.2310 1.0 5.0 
DOPG CAD 13.21 0.5 100 0.9848 1.2360 0.5 1.0 
DPPS CAD 12.09 1.0 100 0.9827 0.2822 1.0 2.5 
DOPS CAD 12.75 0.5 100 0.9838 0.1680 1.0 10 
POPS CAD 12.10 1.0 100 0.9764 0.3072 2.5 10 
Brain PS CAD 12.44 10 500 0.9753 0.7449 10 25 
ESM CAD 9.96 1.0 1000 0.9904 0.9270 1.0 5.0 
DSPE-mPEG-2000 CAD 14.76 0.5 50 0.9806 0.1076 0.5 25 
Cholesterol CAD 7.71 0.5 100 0.9902 0.1367 0.5 2.5 
DiO DAD 16.62 0.02 22 0.9998 0.0689 < 0.02 < 0.02 
DiD DAD 18.33 0.03 26 0.9988 0.3436 < 0.03 < 0.03 
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Figure S1. Reproducibility of the HPLC method shown for three different phospholipids, (a) DPPC, (b) DOPC and 
(c) POPC. Single points on the calibration curve are shown as mean ± SD (n=3). A regression line by the method 
of least squares is plotted with the 95% confidence interval. 
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Figure S2. Robustness test of the HPLC method: overlaid chromatograms of mixed, DPPC, DOPC and POPC 
after being analyzed in altered conditions, (a) column oven temperature, (b) flow rate, (c) CAD gas evaporation 
temperature. 
 
 
 
 
 
 
 
Figure S3. Changes in (a) size and PDI and (b) zeta potential of liposomal formulation after photodegradation. 
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Table S1. Overview of results from the accuracy test. Deviation of determined concentration of DPPC, DOPC and 
POPC at different levels from the nominal concentration (n = 5).  
Sample 
concentration 
Deviation from nominal concentration [%] 
DPPC DOPC POPC 
100 µg/mL 2.35 ± 1.02 2.14 ± 1.13 3.90 ± 1.16 
50 µg/mL 5.66 ± 1.39 5.15 ± 1.15 1.42 ± 1.08 
25 µg/mL 1.53 ± 1.24 3.42 ± 1.59 1.79 ± 0.61 
 
 
Table S2. Overview of results obtained by robustness test. Deviation of determined concentrations of combined 
AUC of DPPC, DOPC and POPC from the nominal concentration after the analysis in altered conditions. 
Alteration 
Deviation from the nominal value [%] 
AUC Retention time 
Flow rate:  
0.675 mL/min 5.51 ± 1.27 2.51 ± 0.04 
Flow rate:  
0.65 mL/min 5.88 ± 0.94 4.33 ± 0.09 
Column oven: 48 °C 1.60 ± 1.04 3.41 ± 0.10 
Column oven: 52 °C 2.15 ± 1.04 2.66 ± 0.05 
CAD: 40 °C 0.26 ± 0.04 0.24 ± 0.04 
CAD: 50 °C 0.55 ± 0.02 0.20 ± 0.08 
 
 
